Merck
  • Home
  • Search Results
  • Imaging the folate receptor on cancer cells with 99mTc-etarfolatide: properties, clinical use, and future potential of folate receptor imaging.

Imaging the folate receptor on cancer cells with 99mTc-etarfolatide: properties, clinical use, and future potential of folate receptor imaging.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine (2014-04-16)
Alan H Maurer, Philip Elsinga, Stefano Fanti, Binh Nguyen, Wim J G Oyen, Wolfgang A Weber
ABSTRACT

Folate receptor (FR) can be used as a therapeutic target because of its expression on different epithelial cancers, such as ovarian, non-small cell lung, endometrial, and breast cancer. Assessing FR expression in tumors may help to identify patients who can benefit from FR-targeted therapeutics, such as vintafolide and farletuzumab. Different methods exist to detect FR expression. Tissue sampling has limited clinical utility, mainly because it requires an invasive procedure. (99m)Tc-etarfolatide, a (99m)Tc-labeled folate conjugate, is in late-phase trials in Europe and the United States. It allows noninvasive, whole-body imaging of the FR. This review focuses on this FR-imaging agent and how it may be used to direct FR-targeted therapy.

MATERIALS
Product Number
Brand
Product Description

Supelco
Folic acid, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Folic acid, United States Pharmacopeia (USP) Reference Standard
Folic acid, European Pharmacopoeia (EP) Reference Standard
Supelco
Folic acid, analytical standard
Sigma-Aldrich
Folic acid, ≥97%
Sigma-Aldrich
Folic acid, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥97%
Sigma-Aldrich
Folic acid, meets USP testing specifications